drugset / Trial / NCT05664074
Rectal Indomethacin vs Intravenous Ketorolac
RandomizedParallel-groupSingle-blindPrevention
Summary
Endoscopic retrograde cholangiopancreatography (ERCP) is an essential procedure that can be complicated by post-ERCP pancreatitis (PEP). Indomethacin and ketorolac are two medications used to prevent PEP. The main reason for this research study is to compare the effectiveness these drugs at reducing rates of PEP. There have been no studies comparing the effectiveness of these medications in preventing PEP in pediatric patients. You are being asked to take part in this research study because you are scheduled to have an ERCP as part of your medical care.
Timeline
- Start
- 2022-11-07
- Primary completion
- 2025-02-05
- Completion
- 2025-02-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Indomethacin | Small molecule | 25 mg | Rectal |
| Subject | Indomethacin | Small molecule | 50 mg | Rectal |
| Subject | Indomethacin | Small molecule | 100 mg | Rectal |
| Subject | Ketorolac | Other / unclassified | 0.5 mg/kg | Intravenous |